Suppr超能文献

1975 年至 2006 年美国对侧乳腺癌发病率下降。

Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

机构信息

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

出版信息

J Clin Oncol. 2011 Apr 20;29(12):1564-9. doi: 10.1200/JCO.2010.32.7395. Epub 2011 Mar 14.

Abstract

PURPOSE

Contralateral breast cancer (CBC) is the most frequent new malignancy among women diagnosed with a first breast cancer. Although temporal trends for first breast cancers have been well studied, trends for CBC are not so well established.

PATIENTS AND METHODS

We examined temporal trends in CBC incidence using US Surveillance, Epidemiology, and End Results database (1975 to 2006). Data were stratified by estrogen receptor (ER) status of the first breast cancer for the available time period (1990+). We estimated the annual percent change (EAPC) in CBC rates using Poisson regression models adjusted for the age at and time since first breast cancer diagnosis.

RESULTS

Before 1985, CBC incidence rates were stable (EAPC, 0.27% per year; 95% CI, -0.4 to 0.9), after which they declined with an EAPC of -3.07% per year (95% CI, -3.5 to -2.7). From 1990 forward, the declines were restricted to CBC after an ER-positive cancer (EAPC, -3.18%; 95% CI, -4.2 to -2.2) with no clear decreases after an ER-negative cancer. Estimated current age-specific CBC rates (per 100/year) after an ER-positive first cancer were: 0.45 for first cancers diagnosed before age 30 years and 0.25 to 0.37 for age 30 years or older. Rates after an ER-negative cancer were higher: 1.26 before age 30 years, 0.85 for age 30 to 35 years, and 0.45 to 0.65 for age 40 or older.

CONCLUSION

Results show a favorable decrease of 3% per year for CBC incidence in the United States since 1985. This overall trend was driven by declining CBC rates after an ER-positive cancer, possibly because of the widespread usage of adjuvant hormone therapies, after the results of the Nolvadex Adjuvant Trial Organisation were published in 1983, and/or other adjuvant treatments.

摘要

目的

对侧乳腺癌(CBC)是女性首次确诊乳腺癌后最常见的新发恶性肿瘤。尽管首次乳腺癌的时间趋势已得到充分研究,但 CBC 的时间趋势尚不确定。

患者和方法

我们使用美国监测、流行病学和最终结果数据库(1975 年至 2006 年)检查了 CBC 发病率的时间趋势。根据首次乳腺癌的雌激素受体(ER)状态,将数据分层为可获得的时间段(1990+)。我们使用泊松回归模型估计 CBC 发生率的年百分变化(EAPC),该模型调整了首次乳腺癌诊断时和诊断后的年龄。

结果

1985 年之前,CBC 发病率稳定(EAPC,每年 0.27%;95%CI,-0.4 至 0.9),此后每年下降 3.07%(95%CI,-3.5 至 -2.7)。从 1990 年开始,下降仅限于 ER 阳性癌症后的 CBC(EAPC,-3.18%;95%CI,-4.2 至 -2.2),而 ER 阴性癌症后则没有明显下降。ER 阳性首次癌症后估计的当前年龄特异性 CBC 发生率(每 100/年)为:30 岁以下首次癌症诊断前为 0.45,30 岁或以上为 0.25 至 0.37。ER 阴性癌症后的发生率较高:30 岁以下为 1.26,30 至 35 岁为 0.85,40 岁或以上为 0.45 至 0.65。

结论

结果表明,自 1985 年以来,美国 CBC 发病率每年下降 3%。这一总体趋势是由 ER 阳性癌症后 CBC 发生率下降驱动的,这可能是由于诺雷德辅助试验组织(Nolvadex Adjuvant Trial Organisation)的结果于 1983 年公布后,广泛使用辅助激素治疗以及/或其他辅助治疗所致。

相似文献

引用本文的文献

4
Hormone Receptor Positive Breast Cancer in Young Women: A Review.年轻女性激素受体阳性乳腺癌:综述
J Surg Oncol. 2025 Mar;131(4):580-586. doi: 10.1002/jso.27963. Epub 2024 Oct 29.
10
Explaining risks and benefits of loco-regional treatments to patients.向患者解释局部治疗的风险和获益。
Breast. 2023 Oct;71:132-137. doi: 10.1016/j.breast.2023.08.006. Epub 2023 Aug 22.

本文引用的文献

2
Qualitative age interactions in breast cancer studies: mind the gap.乳腺癌研究中的定性年龄相互作用:注意差距。
J Clin Oncol. 2009 Nov 10;27(32):5308-11. doi: 10.1200/JCO.2009.22.9450. Epub 2009 Oct 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验